The Headline You’re Being Sold

The mainstream media wants you to believe that the FDA crackdown on compounded tirzepatide and other GLP-1 drugs is about “patient safety.” You’ll hear it from health reporters, pharmaceutical spokespeople, and so-called “regulatory experts”: compounders are dangerous, uncontrolled, risky. The FDA is protecting you.

This is a lie wrapped in bureaucratic language and served with a side of manufactured concern.

The real story is far simpler and far more infuriating: Eli Lilly made $10.1 billion from tirzepatide sales in Q3 2025 alone, and they will not tolerate a $200 generic alternative stealing their market share. The FDA, captured by pharmaceutical interests, is their enforcer.

I’m calling it out because that’s what I do. I tell you the truth about health, medicine, and the systems designed to keep you dependent, weak, and profitable.

Who I Am and Why This Matters

My name is Tony Huge. I’m a medical lawyer with a J.D., and I’ve spent years investigating the dark intersection of pharma, regulators, and medical truth. I’ve been called the most censored voice in health — not because I’m wrong, but because I expose what the system doesn’t want you to know.

I’ve been banned from social media, sued, investigated, and attacked by establishment players. Why? Because I refuse to accept that your health is a commodity to be rationed based on corporate profit margins.

Medical freedom is not a talking point for me. It’s a mission.

And right now, that mission requires me to expose what’s happening with tirzepatide: how a life-changing medication is being artificially gatekept, how patients are being denied access to the tool that could transform their metabolic health, and how the FDA is complicit in one of the most nakedly obvious examples of regulatory capture I’ve seen in my career.

The Compounding Ban Is About Money, Not Safety

Let’s start with the core claim: compounded GLP-1s are unsafe.

The data says otherwise.

According to FAERS (FDA Adverse Event Reporting System) analysis, compounded tirzepatide and other GLP-1 drugs accounted for just 0.87% of all GLP-1 adverse event reports — 707 reports out of 81,078 total. That’s remarkable. If compounded products were significantly more dangerous, you’d expect that number to be substantially higher, especially given that they represent a growing segment of the market.

A peer-reviewed clinical study published in the Journal of the American Osteopathic Association in 2025 showed that compounded tirzepatide patients achieved an average weight loss of 38.82 lbs at 24 weeks — efficacy equivalent to branded Mounjaro.

The FDA removed tirzepatide from the official drug shortage list in October 2024. Convenient timing. But here’s what’s critical: compounders were still reporting supply issues and patient demand outpacing availability. If the drug was truly no longer scarce, why were patients still unable to access compounded versions through legitimate channels?

Because the FDA’s goal wasn’t to solve a shortage. It was to declare the shortage solved so they could then claim that compounders were operating without justification, violating the regulations that explicitly allow compounding only when commercial supplies are insufficient.

This is regulatory judo: move the goalposts, then cite the moved goalposts as evidence of wrongdoing.

When the Outsourcing Facilities Association sued the FDA over this action, the court sided with the FDA in May 2025. But legal victory doesn’t equal scientific evidence. The court didn’t find compounded tirzepatide unsafe — it upheld the FDA’s authority to regulate it. That’s a completely different claim.

The safety argument is theater. The real argument is control and profit protection.

The Numbers That Expose Everything

Mounjaro list price: $1,079.77 per month.

Compounded tirzepatide: $200–$300 per month.

That’s a 75–80% price difference for the same active pharmaceutical ingredient, manufactured to USP (United States Pharmacopeia) standards in FDA-licensed facilities.

Now look at Eli Lilly’s revenue: $10.1 billion in tirzepatide sales for Q3 2025 alone. That’s not annual. That’s one quarter. Do you understand the scale of what we’re talking about? The company made more in three months selling tirzepatide than the GDP of dozens of nations.

If compounded alternatives capture even 10% of that market, Eli Lilly loses $1 billion quarterly. That’s the real math driving the FDA crackdown.

Consider what that price gap means in human terms:

• Amanda Bonello, 36, from Iowa, lost 26 lbs in 2 months on compounded tirzepatide. She told reporters: “I absolutely cannot afford the branded version.” She’s not alone. An estimated 70% of Americans believe GLP-1s are only accessible to the wealthy — and they’re right.
• Medicare and Medicaid generally do not cover GLP-1s for weight management — only for type 2 diabetes. So if you’re uninsured (27 million Americans) or on public insurance seeking to optimize your metabolism, you’re locked out of the branded drug entirely.
• One patient I’ve documented lost 52 lbs on compounded tirzepatide and resolved significant autoimmune-driven pain. She couldn’t have afforded the same medication at branded pricing. Should she be denied that outcome because it cuts into Eli Lilly’s quarterly earnings?

Eli Lilly filed 4+ lawsuits against telehealth companies and sued Empower Clinic specifically, claiming patent infringement and brand dilution. Notice what they didn’t claim: that compounded versions are unsafe or ineffective. Because they can’t. The data doesn’t support it.

Strive Specialties filed an antitrust lawsuit against both Eli Lilly and Novo Nordisk, alleging anticompetitive practices designed to block compounders from the market. The federal government should be investigating, not collaborating in the conspiracy.

The Laws of Biochemistry Don’t Care About Patent Expiration

In my book Better Than Natural, I introduced the foundational Tony Huge Laws of Biochemistry Physics that govern human optimization:

Law 4: Every Biological Problem Has a Chemical Solution.

Obesity and type 2 diabetes are biological problems with known pathophysiology. Tirzepatide is a glucagon-like peptide 1 (GLP-1) receptor agonist that addresses that pathophysiology. It’s the chemical solution. The fact that it comes from a compounder instead of Eli Lilly doesn’t change its chemical structure, mechanism of action, or efficacy. The molecule is identical. The biology doesn’t care about corporate ownership.

Yet the FDA and Eli Lilly are attempting to force you into believing that only one source of that chemical solution is legitimate. That’s not science. That’s coercion.

Law 5: The Law of Utility vs. Toxicity.

Every substance exists on a spectrum from utility to toxicity. Tirzepatide’s utility is proven — weight loss, improved metabolic markers, reduced cardiovascular risk. Its toxicity profile at therapeutic doses is well-documented and understood. That profile is identical whether the molecule comes from Eli Lilly’s manufacturing facility or a licensed compounding pharmacy. A molecule is a molecule.

The FDA isn’t banning compounded tirzepatide because of its toxicity profile. It’s banning access because of Freedom vs. Control Politics — the system’s preference for centralized control and corporate profit over individual choice and medical autonomy.

You deserve the freedom to choose whether you access this medication through a branded source or a compounded source. That choice should be informed, transparent, and yours to make. The FDA’s role should be ensuring that both sources meet quality standards — which licensed compounders do.

Instead, the FDA is restricting your choice, narrowing your options, and forcing you into dependency on a single expensive supplier.

Core Value 1: Holistic Excellence demands that you have access to every legitimate tool for optimizing your health and metabolism. Tirzepatide is one such tool. Denying you access to it because a cheaper version threatens corporate revenue is antithetical to your wellbeing and your fundamental right to medical autonomy.

Methodology 1: Knowledge is Freedom.

Censoring information about compounding options, suppressing data about their efficacy and safety, and blocking patient access is a form of epistemic oppression. It’s hiding facts. The system thrives on keeping you ignorant about your options because an informed patient is harder to control and less profitable to exploit.

That’s why I’m writing this. You need to know that the science supports compounded tirzepatide access. You need to know that the safety argument is manufactured. And you need to know that the real motivation is pharmaceutical profit protection.

The System Is Built to Keep You Weak

Here’s the uncomfortable truth: pharmaceutical companies don’t want you to get well. They want you to get dependent.

A patient on tirzepatide at $1,079.77 per month is a permanent customer. That’s $12,957 annually. Over a decade, assuming no price increases (which is naive), that’s $129,570. Multiply that by millions of patients, and you’re looking at multi-billion-dollar revenue streams that don’t require innovation — just price maintenance and regulatory gatekeeping.

If you can access the same drug for $200–$300 monthly? That’s $2,400–$3,600 annually. You’re no longer locked into permanent, expensive dependency. You become economically self-sufficient with your healthcare. That’s antithetical to the pharma business model.

The FDA crackdown serves one function: to collapse the price-competitive alternative so that Eli Lilly’s premium pricing becomes the only option. It’s not about safety. It’s about economic coercion.

And here’s what enrages me: the people being hurt most are the ones who can least afford it. The uninsured. The underinsured. The patients on fixed incomes. The working class that doesn’t have access to premium healthcare plans that might cover tirzepatide for weight management. They’re being denied a tool that could transform their lives — their actual metabolic health, their mobility, their relationship with their body — because Eli Lilly’s quarterly earnings might dip by a few percentage points.

That’s not medicine. That’s extraction.

The Path Forward: RFK Jr. and the Possibility of Change

Robert F. Kennedy Jr., as HHS secretary, has been expected to take a more lenient stance toward compounders. There’s also been discussion about potential Medicare and Medicaid coverage expansions for GLP-1s — which would democratize access across populations currently locked out of treatment.

That’s the policy intervention we need: not to eliminate branded options, but to restore competitive balance. Let Eli Lilly sell Mounjaro at whatever price they choose. But also allow compounders to manufacture the same active ingredient at market rates. Let patients and doctors choose based on cost, access, and individual need — not regulatory fiat designed to protect shareholders.

Real innovation requires real competition. Real medical freedom requires real choice.

My Commitment to You

I will continue to expose these stories because they matter. Not because I have an ideological axe to grind with the FDA or Eli Lilly (though I do), but because your health is not a commodity. Your access to the tools that could optimize your metabolism, extend your lifespan, reduce your disease risk — that’s a human right, not a privilege rationed by regulatory capture.

The media won’t tell you this story. The establishment health commentators won’t touch it. And that’s exactly why I have to.

You deserve to know the truth: the science supports compounded tirzepatide. The safety data backs it. The price difference reflects market failure, not product quality. And the FDA crackdown serves profit protection, not patient protection.

That’s the story. That’s the scandal. And I’m not going to stop talking about it.